1. Home
  2. APLM vs JL Comparison

APLM vs JL Comparison

Compare APLM & JL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • JL
  • Stock Information
  • Founded
  • APLM 2016
  • JL 1985
  • Country
  • APLM United States
  • JL Hong Kong
  • Employees
  • APLM N/A
  • JL N/A
  • Industry
  • APLM Blank Checks
  • JL
  • Sector
  • APLM Finance
  • JL
  • Exchange
  • APLM Nasdaq
  • JL NYSE
  • Market Cap
  • APLM 15.6M
  • JL 13.7M
  • IPO Year
  • APLM N/A
  • JL 2024
  • Fundamental
  • Price
  • APLM $0.13
  • JL $0.38
  • Analyst Decision
  • APLM Strong Buy
  • JL
  • Analyst Count
  • APLM 2
  • JL 0
  • Target Price
  • APLM $4.25
  • JL N/A
  • AVG Volume (30 Days)
  • APLM 872.1K
  • JL 308.8K
  • Earning Date
  • APLM 08-14-2024
  • JL 11-02-2024
  • Dividend Yield
  • APLM N/A
  • JL N/A
  • EPS Growth
  • APLM N/A
  • JL N/A
  • EPS
  • APLM N/A
  • JL 0.03
  • Revenue
  • APLM $2,101,000.00
  • JL $28,378,669.00
  • Revenue This Year
  • APLM N/A
  • JL N/A
  • Revenue Next Year
  • APLM N/A
  • JL N/A
  • P/E Ratio
  • APLM N/A
  • JL $13.92
  • Revenue Growth
  • APLM 70.54
  • JL N/A
  • 52 Week Low
  • APLM $0.11
  • JL $0.30
  • 52 Week High
  • APLM $2.15
  • JL $29.95
  • Technical
  • Relative Strength Index (RSI)
  • APLM 45.47
  • JL 42.21
  • Support Level
  • APLM $0.13
  • JL $0.38
  • Resistance Level
  • APLM $0.17
  • JL $0.44
  • Average True Range (ATR)
  • APLM 0.01
  • JL 0.04
  • MACD
  • APLM 0.00
  • JL -0.00
  • Stochastic Oscillator
  • APLM 26.03
  • JL 4.52

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About JL J-LONG GROUP LIMITED

J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.

Share on Social Networks: